Forsøksdyr: Role of TG2, TG2-specific B cells and gluten-specific B cells in celiac disease

Godkjenningsdato 05.02.2020

Godkjenningsperiode 10.02.2020-09.02.2024

1 Purpose
Transglutaminase 2 (TG2) is thought to have a critical role in celiac disease, and the enzyme is also the target of disease-specific autoantibodies. The mechanisms, kinetics and location of TG2 activation, and how the antibody response to TG2 and gluten is induced, are not understood, and will be studied in this project.
2 Distress
Most animals in this project will only suffer from minimal distress for short time due to the intravenous, intraperitoneal, subcuteaneous or oral administration of cells or antigen, in the presence of the adjuvants cholera toxin or CFA, as well as due to withdrawal of blood.
3 Expected benefit
A better understanding is crucial for our understanding of celiac disease pathogenesis, and will enable the development of improved drugs that inhibit TG2 activity in patients.
4 Number of animals, and what kind
The application includes 1174 mice in total. Wild type C57Bl/6 mice, TG2KO mice, and humanized mice expressing the celiac disease risk allele HLA-DQ2, and mice expressing celiac patient derived gluten-specific T-cell receptors, or B-cell receptors recognizing TG2 and gluten. In addition, we will make conditional KO mice for TG2 specifically in enterocytes using Villin-Cre and TG2-flox/flox transgenic mice.
5 How to adhere to 3R
We will minimize the amount of distress by keeping injection volumes low. We also use the minimal number of mice to get valid answers in our experiments.